ABOUT
LEXTRO LABS
Lextro Labs Private Limited is a discovery-stage biopharmaceutical company engaged in the development of first-in-class and best-in-class biotherapeutics through “Immune modulation and Cytotoxicity, (ImCy) a platform technology”. ImCy restores underlying homeostatic mechanisms such that long lasting responses are attained in indications such as Cancer, Autoimmune, Metabolic and Infectious diseases.
LEADERSHIP
LEADERSHIP
Akkina Srinivas Chowdary
MCA, MBA
founder & Managing Director
Akkina Srinivas Chowdary, an MBA, is the Director of Venkateshwara Minerals since 2006. He has successfully led the company’s growth and expansion into new areas – evolving from mining, logistics and financial investments into futuristic, new age businesses like biologics. Lextro leverages his vision and expertise to tap into new markets and revenue streams. Passionate about sports and grooming talent, he has helped provide sports facilities and serves as the President of the Football Association in his district.
Murali K Addepalli
PhD
Co-founder & Chief Scientific Officer
Dr. Murali K Addepalli has 20+ years’ experience in drug discovery and development of novel immune-therapeutics for oncology, autoimmune and infectious diseases. After obtaining his PhD from Nagasaki University (Japan), he gained valuable experience at NIH, Bethesda (USA) as a Post-doctoral Fellow. He has a proven track record of creating therapeutic pipelines and generating a significant IP portfolio (9 patents) at leading Big Pharma companies including Nektar Therapeutics, Biocon Bristol Myers Squibb and Reliance Life Sciences. He worked in 15+ discovery programs in various capacities, including Biology Lead, Program Lead, and was instrumental in several IND filings.
SCIENCE & TECHNOLOGY
OUR SCIENCE
Lextro is developing therapies that are multi-specific in nature and aim to restore homeostasis mechanisms such that rejuvenation in health can be achieved.
Our approach includes:
- Identification of disease pathways and underlying dysregulated areas for a given indication
- Restoration of homeostasis in disease governing pathways by combining agonists or antagonists while ensuring the utmost safety profile
- Elimination or minimization of drug-induced debilitating effects by obtaining durable responses to treatment
- Identification of disease pathways and underlying dysregulated areas for a given indication
- Restoration of homeostasis in disease governing pathways by combining agonists or antagonists while ensuring the utmost safety profile
- Restoration of homeostasis in disease governing pathways by combining agonists or antagonists while ensuring the utmost safety profile
- Identification of disease pathways and underlying dysregulated areas for a given indication
- Restoration of homeostasis in disease governing pathways by combining agonists or antagonists while ensuring the utmost safety profile
- Restoration of homeostasis in disease governing pathways by combining agonists or antagonists while ensuring the utmost safety profile
OUR THERAPEUTIC PIPELINE
Lextro is a leading Immune modulation & Cytotoxicity focused company developing first-in-class & best-in-class therapeutics for the treatment of Autoimmune, Cancer, Metabolic and Infectious diseases. Our proprietary product pipeline showcases our dedication to revolutionizing healthcare through innovation. Each of our therapies is designed to be multi-specific, addressing specific disease pathways and restoring homeostasis mechanisms to achieve rejuvenation in health.
